Antiviral Drugs From Basic Discovery Through Clinical Trials

by Kazmierski, Wieslaw M.

• ISBN13: 9780470455630
• ISBN10: 0470455632
• Edition: 1st
• Format: Hardcover
• Copyright: 2011-08-23
• Publisher: Wiley
• More Book Details
• Purchase Benefits

Summary

This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense sourcing references. Topics showcase challenges and solutions of issues encountered, offering tremendous experience accumulated over many years of research that will be particularly useful to basic and bench scientists as well as clinicians as they continue discovering and developing new drugs and therapies.

Author Biography

Wieslaw M. Kazmierski, PhD, has worked on novel HIV and HCV therapies in both small and large pharma settings in the last two decades, helping to advance molecules to clinical trials. Dr. Kazmierski has authored numerous peer reviewed publications and has been named a co-inventor on many patents. He has edited scientific books and had served on journal editorial boards.

Table of Contents

Human Immunodeficiency Virus (HIV)

HIV Protease Inhibitors

Atazanavir

PLâÇô100: A Novel HIVâÇô1 Protease Inhibitor

Darunavir (Prezista“, TMC114): from bench to clinic, improving treatment options for HIVâÇôinfected patients

Discovery and Development o Tipranavir

HIV NonâÇôNucleoside Reverse Transcriptase Inhibitors

TMC278 (rilpivirine): a nextâÇôgeneration NNRTI in Phase III clinical development for treatmentâÇônaÔve patients

Etravirine: from TMC125 to Intelenceâäó âÇô a treatment paradigm shift for HIVâÇôinfected patients

Nucleoside Reverse Transcriptase Inhibitors

Tenofovir Disoproxil Fumarate (Tdf): Discovery and Clinical Development

Discovery and Clinical Development of Apricitabine

HIV Inhibitors

Discovery and Development of Maraviroc and PFâÇô232798: CCR5 Antagonists for the treatment of HIVâÇô1 infection

Discovering of the CCR5 Antagonist Vicriviroc (SCH 417690/SCHâÇôD) For Treatment of HIVâÇô1 Infection

Discovery and Development of HIVâÇô1 Entry Inhibitors That Target gp120

HIV Integrase Inhibitors

Discovery of MKâÇô0536: A Potential Second Generation HIVâÇô1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation

Discovery and Development of HIV Integrase Inhibitor Realegravir

Elvitegravir, A Novel Monoketo Acid HIVâÇô1 Integrase Strand Transfer Inhibitor Hisashi Shinkai, Masanori Sato and Yuji Matsuzaki)

Hepatitis C Virus

Protease Inhibitors

Telaprevir

Discovery and Development of BILN 2061 and FollowâÇôup Bl 201335

Intervention of Hepatitis C Replication through NS3âÇô4A Protease Inhibitor, Boceprevir

Discovery & Development of ITMN 191 (R7227)

Discovery and Development of the HCV Protease Inhibitor TMC435

HCV Polymerase Nucleoside Inhibitors

Dicovery and clinical evaluation of the nucleoside analog Balapiravir

Discovery and Development of PSIâÇô6130 / RG7128

Other HCV Inhibitor

Discovering of cyclophilin inhibitor NIM811 as a novel therapeutic agent for HCV

HCV viral entry inhibitors

Respiratory Syncytial Virus Inhibitors

Discovery of the RSV inhibitor TMC353121

The discovery and development of orally active RSV fusion inhibitors

Discovery and Development of RSV60449

InfluenzaïǼ Hepatitis B and Cyromegalovirus Inhibitors

Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza

Discovery and Development of Entecavir

Benzimidazole ribonucleosides: Novel drug candidates for the prevention and treatment of cytomegalovirus diseases

Table of Contents provided by Publisher. All Rights Reserved.